Seattle Genetics is a biotechnology company that develops and commercializes monoclonal antibody-based therapies to treat cancer, autoimmune ailments, and other acute medical conditions. The biotechnology company is an industry leader in developing antibody-drug conjugates (ADCs), a technology used to harness the targeting capability of monoclonal antibodies to inject cell-killing agents to cancer cells.
The biotechnology company has three platform technologies namely; antibody-directed enzyme prodrug therapy (ADEPT), engineered monoclonal antibodies, and antibody-drug conjugates (ADCs). Seattle Genetics has created a diverse portfolio of products aimed at treating many types of cancers and is still making significant research activities to advance its ADC technology. Currently, the firm has more than 20 ADCs in clinical development phase.
To commercialize its products to a wider market, Seattle Genetics has agreements for their ADC technology with several pharmaceutical and biotechnology organizations. The companies include Eos Biotechnology, Celldex Therapeutics, Inc., GlaxoSmithKline LLC, Celltech Group, Genencor International, Medarex and Bristol-Myers Squibb. Additionally, the firm has partnership agreements with Takeda Pharmaceutical Company previously known as Millennium to develop and commercialize ADCETRIS. The partnership has made ADCETRIS a global brand that is used in more than 60 countries.
Under Clay Siegall’s leadership, Seattle Genetics has been successful in its efforts to develop advanced cancer treatment therapies. Dr. Siegall is the co-founder, president, chief executive officer and chairperson of the Seattle’s board. He has played an integral part in transforming the biotechnology company from a start-up to a publicly-traded company with an extensive pipeline of monoclonal antibody-based products.
Clay Siegall has a B.S. in Zoology from the University of Maryland and a PhD in Genetics from George Washington University. In 1988, Dr. Siegall started his career at the National Cancer Institute and the National Institutes of Health. Later in 1991, he worked for the Bristol-Myers Squibb Pharmaceutical Research Institute until 1997 when he co-founded Seattle Genetics.